Publicacions en col·laboració amb investigadors/es de Hospital Clínico San Carlos de Madrid (10)

2022

  1. Prospective associations between a priori dietary patterns adherence and kidney function in an elderly Mediterranean population at high cardiovascular risk

    European Journal of Nutrition, Vol. 61, Núm. 6, pp. 3095-3108

2019

  1. Cohort profile: Design and methods of the PREDIMED-Plus randomized trial

    International Journal of Epidemiology, Vol. 48, Núm. 2, pp. 387-388o

2015

  1. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies

    Molecular Genetics and Metabolism, Vol. 114, Núm. 2, pp. 248-258

2013

  1. Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout mice

    PLoS ONE, Vol. 8, Núm. 12

2010

  1. Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes

    Diabetes, Vol. 59, Núm. 6, pp. 1292-1301

2007

  1. Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques

    European Journal of Pharmacology, Vol. 562, Núm. 1-2, pp. 119-129

  2. Lipid cartography of atherosclerotic plaque by cluster-TOF-SIMS imaging

    Analyst, Vol. 132, Núm. 1, pp. 24-26

2006

  1. Modulación mediante tratamiento con atorvastatina y/o amlodipino del perfil de proteínas liberadas por placas ateroscleróticas humanas

    Clínica e investigación en arteriosclerosis, Vol. 18, Núm. 5, pp. 167-175

2003

  1. Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet

    Cardiovascular Research, Vol. 57, Núm. 1, pp. 168-177

2002

  1. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells

    Atherosclerosis, Vol. 160, Núm. 1, pp. 49-58